Acute urinary morbidity following I-125 prostate brachytherapy

Toshio Ohashi, Atsunori Yorozu, Kazuhito Toya, Shiro Saito, Tetsuo Momma

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background. In Japan, iodine-125 (I-125) prostate brachytherapy has been legally approved since July 2003, and this method is becoming more popular. The purpose of the present study was to assess acute urinary morbidity within the first 6 months after I-125 prostate brachytherapy. Methods. A group of 130 consecutive patients with loca-lized prostate cancer was treated with I-125 prostate brachytherapy between September 2003 and June 2004, either alone (monotherapy; 66 patients) or in combination with external-beam radiotherapy (combined therapy; 64 patients). Urinary morbidity was evaluated using the National Cancer Institute - Common Terminology Criteria for Adverse Events, version 3.0. Results. During the follow-up, 111 patients (85.4%) developed some degree of urinary symptoms such as frequency, retention, dysuria, incontinence, or hematuria. Urinary frequency (73.1%) and retention (66.9%) were the most common, and showed no significant differences between the monotherapy group and combined therapy group (P = 0.352 and P = 0.630, respectively). Six patients (4.6%) required catheterization for urinary obstruction; the median timeto onset was 1.5 days (range, 1-192 days). Five of these 6 patients received monotherapy and the other received combined therapy. Conclusion. Manifestations of acute urinary morbidity, especially frequency and retention, are relatively common but acceptable events after I-125 prostate brachytherapy.

Original languageEnglish
Pages (from-to)262-268
Number of pages7
JournalInternational Journal of Clinical Oncology
Volume10
Issue number4
DOIs
Publication statusPublished - 2005 Aug
Externally publishedYes

Fingerprint

Brachytherapy
Prostate
Morbidity
Urinary Catheterization
Dysuria
National Cancer Institute (U.S.)
Hematuria
Group Psychotherapy
Terminology
Iodine
Prostatic Neoplasms
Japan
Radiotherapy
Therapeutics

Keywords

  • Brachytherapy
  • Catheterization
  • Iodine-125
  • Prostate cancer
  • Urinary morbidity

ASJC Scopus subject areas

  • Oncology

Cite this

Acute urinary morbidity following I-125 prostate brachytherapy. / Ohashi, Toshio; Yorozu, Atsunori; Toya, Kazuhito; Saito, Shiro; Momma, Tetsuo.

In: International Journal of Clinical Oncology, Vol. 10, No. 4, 08.2005, p. 262-268.

Research output: Contribution to journalArticle

Ohashi, Toshio ; Yorozu, Atsunori ; Toya, Kazuhito ; Saito, Shiro ; Momma, Tetsuo. / Acute urinary morbidity following I-125 prostate brachytherapy. In: International Journal of Clinical Oncology. 2005 ; Vol. 10, No. 4. pp. 262-268.
@article{0a20d4f21da645ab89ae69c4e9cd91c9,
title = "Acute urinary morbidity following I-125 prostate brachytherapy",
abstract = "Background. In Japan, iodine-125 (I-125) prostate brachytherapy has been legally approved since July 2003, and this method is becoming more popular. The purpose of the present study was to assess acute urinary morbidity within the first 6 months after I-125 prostate brachytherapy. Methods. A group of 130 consecutive patients with loca-lized prostate cancer was treated with I-125 prostate brachytherapy between September 2003 and June 2004, either alone (monotherapy; 66 patients) or in combination with external-beam radiotherapy (combined therapy; 64 patients). Urinary morbidity was evaluated using the National Cancer Institute - Common Terminology Criteria for Adverse Events, version 3.0. Results. During the follow-up, 111 patients (85.4{\%}) developed some degree of urinary symptoms such as frequency, retention, dysuria, incontinence, or hematuria. Urinary frequency (73.1{\%}) and retention (66.9{\%}) were the most common, and showed no significant differences between the monotherapy group and combined therapy group (P = 0.352 and P = 0.630, respectively). Six patients (4.6{\%}) required catheterization for urinary obstruction; the median timeto onset was 1.5 days (range, 1-192 days). Five of these 6 patients received monotherapy and the other received combined therapy. Conclusion. Manifestations of acute urinary morbidity, especially frequency and retention, are relatively common but acceptable events after I-125 prostate brachytherapy.",
keywords = "Brachytherapy, Catheterization, Iodine-125, Prostate cancer, Urinary morbidity",
author = "Toshio Ohashi and Atsunori Yorozu and Kazuhito Toya and Shiro Saito and Tetsuo Momma",
year = "2005",
month = "8",
doi = "10.1007/s10147-005-0507-8",
language = "English",
volume = "10",
pages = "262--268",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Acute urinary morbidity following I-125 prostate brachytherapy

AU - Ohashi, Toshio

AU - Yorozu, Atsunori

AU - Toya, Kazuhito

AU - Saito, Shiro

AU - Momma, Tetsuo

PY - 2005/8

Y1 - 2005/8

N2 - Background. In Japan, iodine-125 (I-125) prostate brachytherapy has been legally approved since July 2003, and this method is becoming more popular. The purpose of the present study was to assess acute urinary morbidity within the first 6 months after I-125 prostate brachytherapy. Methods. A group of 130 consecutive patients with loca-lized prostate cancer was treated with I-125 prostate brachytherapy between September 2003 and June 2004, either alone (monotherapy; 66 patients) or in combination with external-beam radiotherapy (combined therapy; 64 patients). Urinary morbidity was evaluated using the National Cancer Institute - Common Terminology Criteria for Adverse Events, version 3.0. Results. During the follow-up, 111 patients (85.4%) developed some degree of urinary symptoms such as frequency, retention, dysuria, incontinence, or hematuria. Urinary frequency (73.1%) and retention (66.9%) were the most common, and showed no significant differences between the monotherapy group and combined therapy group (P = 0.352 and P = 0.630, respectively). Six patients (4.6%) required catheterization for urinary obstruction; the median timeto onset was 1.5 days (range, 1-192 days). Five of these 6 patients received monotherapy and the other received combined therapy. Conclusion. Manifestations of acute urinary morbidity, especially frequency and retention, are relatively common but acceptable events after I-125 prostate brachytherapy.

AB - Background. In Japan, iodine-125 (I-125) prostate brachytherapy has been legally approved since July 2003, and this method is becoming more popular. The purpose of the present study was to assess acute urinary morbidity within the first 6 months after I-125 prostate brachytherapy. Methods. A group of 130 consecutive patients with loca-lized prostate cancer was treated with I-125 prostate brachytherapy between September 2003 and June 2004, either alone (monotherapy; 66 patients) or in combination with external-beam radiotherapy (combined therapy; 64 patients). Urinary morbidity was evaluated using the National Cancer Institute - Common Terminology Criteria for Adverse Events, version 3.0. Results. During the follow-up, 111 patients (85.4%) developed some degree of urinary symptoms such as frequency, retention, dysuria, incontinence, or hematuria. Urinary frequency (73.1%) and retention (66.9%) were the most common, and showed no significant differences between the monotherapy group and combined therapy group (P = 0.352 and P = 0.630, respectively). Six patients (4.6%) required catheterization for urinary obstruction; the median timeto onset was 1.5 days (range, 1-192 days). Five of these 6 patients received monotherapy and the other received combined therapy. Conclusion. Manifestations of acute urinary morbidity, especially frequency and retention, are relatively common but acceptable events after I-125 prostate brachytherapy.

KW - Brachytherapy

KW - Catheterization

KW - Iodine-125

KW - Prostate cancer

KW - Urinary morbidity

UR - http://www.scopus.com/inward/record.url?scp=24144478966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144478966&partnerID=8YFLogxK

U2 - 10.1007/s10147-005-0507-8

DO - 10.1007/s10147-005-0507-8

M3 - Article

C2 - 16136372

AN - SCOPUS:24144478966

VL - 10

SP - 262

EP - 268

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 4

ER -